BDTX

Peers: BLSM AVBP TYRA ELVN ERAS BBOT ORIC KZIA NVCT RLAY

| Held by: VTI IWM FESM VXF DFSV SMLF IWN IBB VTWO BSVO

Index	RUT
Market Cap	103.99M
Enterprise Value	10.45M
Income	-42.55M
Sales	0.00M
Book/sh	1.67
Cash/sh	1.92
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	0.00%
Employees	21
IPO	Jan 30, 2020

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.08
P/C	0.94
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	7.28
Current Ratio	7.28
Debt/Eq	0.18
LT Debt/Eq	0.14
Option/Short	Yes / Yes

EPS (ttm)	-0.74
EPS next Y	-0.95
EPS next Q	-0.09
EPS this Y	-258.01%
EPS next Y	-54.56%
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-392.92%
Sales Y/Y TTM	-100.00%
EPS Q/Q	7.10%
Sales Q/Q	-
Earnings	Aug 05 AMC
EPS/Sales Surpr.	13.00% -

Insider Own	19.67%
Insider Trans	0.00%
Inst Own	54.54%
Inst Trans	-5.81%
ROA	-29.21%
ROE	-37.21%
ROIC	-38.97%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.31%
SMA50	-7.16%
SMA200	-17.41%
Trades

Shs Outstand	57.45M
Shs Float	46.15M
Short Float	10.84%
Short Ratio	7.32
Short Interest	5.00M
52W High	4.94 -63.36%
52W Low	1.60 13.12%
Volatility	9.67% 6.97%
ATR (14)	0.13
RSI (14)	46.83
Beta	3.48
Rel Volume	0.57
Avg Volume	683.46K
Volume	254,150

Perf Week	-3.72%
Perf Month	-3.72%
Perf Quarter	4.32%
Perf Half Y	-30.38%
Perf YTD	-25.51%
Perf Year	-52.62%
Perf 3Y	0.00%
Perf 5Y	-76.37%
Perf 10Y	-
Recom	1.38
Target Price	10.00
Prev Close	1.86
Price	1.81
Change %	-2.69%

Consensus

Strong Buy

Avg. Price Target

$10.00

Implied Upside

+452.5%

Analysts11incl. previous ratings

Rating Distribution10 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Dec 03, 2025	Downgrade	GGuggenheim	Buy → Neutral
Nov 18, 2025	Resumed	PPiper Sandler	Overweight	$9	+397.2%
Oct 16, 2025	Resumed	SStifel	Buy	$8	+342.0%
Sep 04, 2025	Initiated	GGuggenheim	Buy	$8	+342.0%
Jul 01, 2025	Resumed	RRaymond James	Outperform	$11	+507.7%
Jul 31, 2024	Initiated	RRaymond James	Outperform	$20	+1,005.0%
Jul 14, 2023	Initiated	PPiper Sandler	Overweight
Jun 30, 2023	Upgrade	SStifel	Hold → Buy	$2 → $10	+452.5%
Jun 28, 2023	Upgrade	HH.C. Wainwright	Neutral → Buy	$11	+507.7%
Jun 27, 2023	Upgrade	WWedbush	Neutral → Outperform	$10	+452.5%
Mar 29, 2022	Downgrade	WWedbush	Outperform → Neutral
Mar 22, 2022	Downgrade	HH.C. Wainwright	Buy → Neutral
Sep 30, 2021	Initiated	SStifel	Hold	$10	+452.5%
Jan 07, 2021	Initiated	WWedbush	Outperform	$45	+2,386.2%
Nov 24, 2020	Initiated	BBerenberg	Buy	$58	+3,104.4%
May 04, 2020	Initiated	HH.C. Wainwright	Buy	$53	+2,828.2%
Feb 24, 2020	Initiated	JJP Morgan	Overweight	$42	+2,220.4%
Feb 24, 2020	Initiated	JJefferies	Buy
Feb 24, 2020	Initiated	CCowen	Outperform
Feb 24, 2020	Initiated	CCanaccord Genuity	Buy	$50	+2,662.4%

Sep-02-26 04:01PM	Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-05-26 04:55PM	Black Diamond: Q2 Earnings Snapshot (Associated Press) +7.26%
04:01PM	Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
May-22-26 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) -35.77%
May-21-26 05:13PM	Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations (GlobeNewswire)
08:00AM	Loading…
May-19-26 08:00AM	Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC (GlobeNewswire) +16.28%
May-07-26 07:46AM	Black Diamond: Q1 Earnings Snapshot (Associated Press)
07:30AM	Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
Apr-21-26 10:40AM	Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO Annual Meeting (GlobeNewswire)
Mar-16-26 04:20PM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-09-26 09:10AM	DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier (Zacks)
Mar-06-26 08:48AM	Black Diamond Therapeutics Teases Next-Quarter PFS Data for Silevertinib at TD Cowen Conference (MarketBeat)
Mar-02-26 04:01PM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.35%
Feb-02-26 09:56AM	Black Diamond Therapeutics, Inc. (BDTX) Price Target Trimmed as Piper Updates Biotech Models and 2026 Catalyst Tracker (Insider Monkey)
09:40AM	Loading…
Jan-23-26 09:40AM	Is Black Diamond Therapeutics (BDTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jan-09-26 12:00PM	What Makes Black Diamond (BDTX) a New Strong Buy Stock (Zacks)
06:23AM	New Strong Buy Stocks for January 9th (Zacks)
Dec-31-25 11:12AM	Black Diamond Therapeutics' Silevertinib Shows 60% Response Rate in Preliminary Phase 2 Lung Cancer Data (Insider Monkey)
Dec-04-25 09:35AM	Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) (Zacks)
Dec-03-25 07:01AM	Black Diamond Therapeutics Announces Preliminary Phase 2 Data for Silevertinib in 1L NSCLC and Plans for a Phase 2 Trial of Silevertinib in GBM (GlobeNewswire) -22.03%
Dec-02-25 04:01PM	Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update (GlobeNewswire) -8.49%
Nov-28-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-12-25 09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks) +5.41%
09:15AM	Black Diamond Therapeutics, Inc. (BDTX) Hits Fresh High: Is There Still Room to Run? (Zacks)
Nov-06-25 04:01PM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
07:37AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Oct-31-25 02:00PM	Should You Buy, Hold, or Sell BDTX Stock Ahead of Q3 Earnings? (Zacks)
Oct-22-25 09:24AM	BDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now? (Zacks) -5.05%
09:20AM	Loading…
Oct-15-25 09:20AM	Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX? (Zacks) +10.37%
Oct-09-25 09:52AM	BDTX Stock Hits 52 Week High: Is There More Room for Growth? (Zacks) +8.27%
09:40AM	Is Medpace (MEDP) Outperforming Other Medical Stocks This Year? (Zacks)
Oct-07-25 09:15AM	Black Diamond Therapeutics, Inc. (BDTX) Hit a 52 Week High, Can the Run Continue? (Zacks)
Sep-25-25 12:53PM	Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment? (Zacks)
Sep-23-25 10:23AM	BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy? (Zacks) -7.31%
Sep-22-25 09:40AM	Has Black Diamond Therapeutics (BDTX) Outpaced Other Medical Stocks This Year? (Zacks)
Sep-16-25 09:47AM	Guggenheim Sets $8 Price Target as Black Diamond Therapeutics, Inc. (BDTX) Prepares Phase 2 Results (Insider Monkey)
Sep-12-25 09:08AM	Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug? (Zacks)
Sep-05-25 10:53AM	BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth? (Zacks)
Sep-04-25 10:46AM	Is the Recent Pipeline Progress on its NSCLC Drug Enough for BDTX? (Zacks)
Aug-19-25 12:00PM	Black Diamond (BDTX) Upgraded to Strong Buy: Here's Why (Zacks)
Aug-18-25 09:40AM	Are Medical Stocks Lagging Black Diamond Therapeutics (BDTX) This Year? (Zacks)
Aug-07-25 07:47AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance) -15.24%
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Jul-15-25 04:58PM	Black Diamond Therapeutics, Inc. (BDTX) Rated Outperform as Lead Drug Shows Promise (Insider Monkey)
May-29-25 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire) +13.07%
May-12-25 04:05PM	Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) +6.71% +10.29%
Apr-26-25 11:00AM	Microsoft, Apple Set To Report Earnings As Markets Watch Out For Core PCE Price Index (Seeking Alpha)
Mar-31-25 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Mar-25-25 12:58AM	Black Diamond Therapeutics Trades Well Below Cash After Lucrative Deal With Servier (SeekingAlpha)
Mar-20-25 10:42AM	Servier and Black Diamond sign deal for solid tumours therapy (Pharmaceutical Technology) +9.30%
Mar-19-25 07:00AM	Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy (GlobeNewswire)
Mar-06-25 04:09PM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-19-25 09:15AM	NAYA Biosciences Announces Nomination of New Board Members (GlobeNewswire)
Jan-12-25 06:05AM	Raymond James Predicts Up to ~930% Rally for These 2 Strong Buy Stocks (TipRanks)
Nov-05-24 09:00AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance) +8.70%
08:00AM	Black Diamond Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-01-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.47%
Oct-07-24 04:01PM	Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway (GlobeNewswire)
Sep-23-24 11:43AM	Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug (Benzinga) -5.46%
07:00AM	Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations (GlobeNewswire)
Sep-22-24 10:00AM	Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC (GlobeNewswire)
Sep-14-24 03:30AM	Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024 (GlobeNewswire)
Aug-08-24 04:05PM	Gyre Therapeutics Announces Appointment of David M. Epstein, Ph.D., to Board of Directors (GlobeNewswire) +6.25%
12:00PM	All You Need to Know About Black Diamond (BDTX) Rating Upgrade to Buy (Zacks)
Aug-06-24 01:53PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q2 2024 (InvestorPlace) -5.57%
07:37AM	Black Diamond: Q2 Earnings Snapshot (Associated Press Finance)
07:30AM	Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Jun-29-24 08:28PM	Is Black Diamond Therapeutics, Inc. (BDTX) a Good Biotech Penny Stock to Buy Right Now? (Insider Monkey)
06:30PM	10 Best Biotech Penny Stocks to Buy Now (Insider Monkey)
Jun-01-24 10:00AM	Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-29-24 08:00AM	Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference (GlobeNewswire)
May-16-24 08:23AM	HC Wainwright Adjusts Price Target on Black Diamond Therapeutics to $11 From $12, Keeps Buy Rating (MT Newswires)
May-10-24 08:46AM	Should You Buy Black Diamond Therapeutics (BDTX) Ahead of Earnings? (Zacks) -9.48%
May-09-24 01:54PM	BDTX Stock Earnings: Black Diamond Therapeutic Beats EPS for Q1 2024 (InvestorPlace)
07:30AM	Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
07:28AM	Black Diamond: Q1 Earnings Snapshot (Associated Press Finance)
Apr-29-24 08:50AM	Black Diamond (BDTX) is on the Move, Here's Why the Trend Could be Sustainable (Zacks)
Apr-25-24 09:55AM	Does Black Diamond (BDTX) Have the Potential to Rally 152.96% as Wall Street Analysts Expect? (Zacks)
Apr-24-24 04:05PM	Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-23-24 07:45AM	Garry Menzel joins GHO Capital as Operating Partner (GlobeNewswire)
Apr-15-24 12:00PM	Black Diamond (BDTX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-11-24 08:00AM	Black Diamond Therapeutics Announces Changes to Board of Directors (GlobeNewswire) +11.85%
Apr-08-24 09:55AM	Wall Street Analysts Predict a 129.25% Upside in Black Diamond (BDTX): Here's What You Should Know (Zacks) +5.73%
Apr-07-24 06:00PM	Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting (GlobeNewswire)
Apr-03-24 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.71%
Mar-22-24 09:55AM	How Much Upside is Left in Black Diamond Therapeutics (BDTX)? Wall Street Analysts Think 95.93% (Zacks) +6.10%
Mar-14-24 05:31AM	Black Diamond Therapeutics Inc (BDTX) Reports Q4 and Full Year 2023 Financials, Advances ... (GuruFocus.com) +8.35%
Mar-12-24 08:32AM	Black Diamond: Q4 Earnings Snapshot (Associated Press Finance) -5.50%
08:00AM	Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-05-24 04:30PM	Black Diamond Therapeutics Announces Upcoming Presentation at AACR Annual Meeting 2024 (GlobeNewswire)
Feb-28-24 08:00AM	Black Diamond Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-04-24 08:00AM	Black Diamond Therapeutics Announces Corporate Update and Expected 2024 Milestones (GlobeNewswire)
Dec-13-23 07:00AM	Black Diamond Therapeutics Announces Topline Results from Phase 1 Dose Escalation Trial of BDTX-1535 in Patients with Recurrent GBM (GlobeNewswire) -9.03%
Nov-07-23 08:00AM	Black Diamond Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-23 08:07AM	Black Diamond Therapeutics Inc (BDTX) Reports Q3 2023 Financial Results and Corporate Update (GuruFocus.com)
07:48AM	Black Diamond: Q3 Earnings Snapshot (Associated Press Finance)
07:45AM	Black Diamond Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)

Show Previous News

Black Diamond Therapeutics, Inc. is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The company's MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type-mediated toxicities, and be brain-penetrant to treat central nervous system diseases. It is currently focused on advancing a Phase 2 NSCLC trial of BDTX-1535, a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR-mutant NSCLC and glioblastoma. The company was founded by David M. Epstein and Elizabeth Buck in 2014 and is headquartered in Cambridge, MA.

Ph.D.Dr. Mark A. Velleca M.D.

J.D.Mr. Brent Hatzis-Schoch Esq.

Ph.D.Dr. Sergey Yurasov M.D.

Co-Founder & Chief Scientific OfficerDr. Elizabeth Buck Ph.D.

Principal Financial OfficerMs. Erika Jones

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Diamond Therapeutics Inc

Upgrade your Finviz experience